For people with heart disease, adjusting statin doses to hit a cholesterol target leads to about the same average 'bad cholesterol' level over 3 years as always using the strongest dose. This finding is from the abstract summary - full study details were not available.
Evidence from Studies
Supporting (1)
Community contributions welcome
Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.
The study found that adjusting statin doses to reach a cholesterol target works just as well as always using a high-dose statin in lowering LDL cholesterol.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Causally determine whether treat-to-target leads to equivalent LDL-C lowering compared to fixed high-intensity statins under controlled conditions.
A double-blind RCT of 4000+ adults aged 50–75 with coronary artery disease, randomized to treat-to-target (LDL-C 50–70 mg/dL with dose titration) vs fixed high-intensity statin (rosuvastatin 20 mg), with LDL-C measured every 3 months over 3 years using standardized assays, intention-to-treat analysis, and central lab verification.
Describe long-term LDL-C trajectories and variability under each strategy in routine care.
A prospective cohort of 8000 patients with coronary artery disease initiating statins, with electronic health record data on prescribed regimen (treat-to-target with documented titration vs fixed high-intensity), and serial LDL-C measurements over 3 years, analyzed using mixed-effects models to compare mean levels and variability.
Estimate the prevalence of target LDL-C attainment across different statin strategies at a single point in time.
A national cross-sectional survey of 5000 adults with coronary artery disease on statins, collecting current LDL-C levels, statin type and dose, and whether treatment was guided by target goals or fixed intensity, with multivariable regression to assess association between strategy and LDL-C <70 mg/dL.